TRYNGOLZA (olezarsen sodium)
ANTIHYPERLIPIDEMIC - APOLIPOPROTEIN SYNTHESIS INHIBITORS · HYPERTRIGLYCERIDEMIA ·+1
Ionis Pharmaceuticals, Inc.
Drug class
Antihyperlipidemic - apolipoprotein Synthesis Inhibitors
Antihyperlipidemic apolipoprotein synthesis inhibitors, most specifically represented by apolipoprotein B-100 synthesis inhibitors such as mipomersen, are specialized lipid-lowering agents designed to target the production of atherogenic lipoproteins. Read more about Antihyperlipidemic - apolipoprotein Synthesis Inhibitors
2 drugs in this class 2 manufacturers
Drugs in Antihyperlipidemic - apolipoprotein Synthesis Inhibitors
REDEMPLO (plozasiran sodium)
ANTIHYPERLIPIDEMIC - APOLIPOPROTEIN SYNTHESIS INHIBITORS · FAMILIAL CHYLOMICRONEMIA SYNDROME
ARROWHEAD PHARM
Filter & compare in the drug finder →
Opens the drug finder with Antihyperlipidemic - apolipoprotein Synthesis Inhibitors preselected. Add indication or manufacturer filters there.
Antihyperlipidemic apolipoprotein synthesis inhibitors, most specifically represented by apolipoprotein B-100 synthesis inhibitors such as mipomersen, are specialized lipid-lowering agents designed to target the production of atherogenic lipoproteins.
These therapies primarily consist of antisense oligonucleotides that bind specifically to messenger RNA encoding apolipoprotein B, prompting enzymatic RNA degradation and thereby suppressing the hepatic synthesis of apolipoprotein B-100.
Because apolipoprotein B is an indispensable structural backbone for the assembly and secretion of very-low-density lipoproteins and low-density lipoproteins, inhibiting its synthesis results in substantial reductions in circulating plasma concentrations of atherogenic lipids, including LDL cholesterol.
Clinically, these agents have been developed and utilized as adjunct therapies to lower lipid concentrations in patients with severe, refractory dyslipidemias, predominantly homozygous familial hypercholesterolemia.
-
fda.gov
Antihyperlipidemic apolipoprotein synthesis inhibitors, most specifically represented by apolipoprotein B-100 synthesis inhibitors such as mipomersen, are specialized lipid-lowering agents designed to target the production of atherogenic lipoproteins Because apolipoprotein B is an indispensable structural backbone for the assembly and secretion of very-low-density lipoproteins and low-density lipoproteins, inhibiting its synthesis results in substantial reductions in circulating plasma concentra...
-
rxlist.com
Antihyperlipidemic apolipoprotein synthesis inhibitors, most specifically represented by apolipoprotein B-100 synthesis inhibitors such as mipomersen, are specialized lipid-lowering agents designed to target the production of atherogenic lipoproteins These therapies primarily consist of antisense oligonucleotides that bind specifically to messenger RNA encoding apolipoprotein B, prompting enzymatic RNA degradation and thereby suppressing the hepatic synthesis of apolipoprotein B-100 Because apol...
-
fda.gov
These therapies primarily consist of antisense oligonucleotides that bind specifically to messenger RNA encoding apolipoprotein B, prompting enzymatic RNA degradation and thereby suppressing the hepatic synthesis of apolipoprotein B-100 Because apolipoprotein B is an indispensable structural backbone for the assembly and secretion of very-low-density lipoproteins and low-density lipoproteins, inhibiting its synthesis results in substantial reductions in circulating plasma concentrations of ather...
-
fda.gov
Clinically, these agents have been developed and utilized as adjunct therapies to lower lipid concentrations in patients with severe, refractory dyslipidemias, predominantly homozygous familial hypercholesterolemia
-
drugbank.com
Clinically, these agents have been developed and utilized as adjunct therapies to lower lipid concentrations in patients with severe, refractory dyslipidemias, predominantly homozygous familial hypercholesterolemia
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.